A carregar...
Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
Osimertinib, a third‐generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), provides marked clinical benefit for patients with EGFR‐activating mutations. Unfortunately, limited treatments exist for patients who acquire osimertinib resistance. We observed two ‘...
Na minha lista:
| Publicado no: | Mol Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7266273/ https://ncbi.nlm.nih.gov/pubmed/32239624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12682 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|